Aster Capital Management DIFC Ltd lowered its holdings in Danaher Co. (NYSE:DHR – Free Report) by 93.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,038 shares of the conglomerate’s stock after selling 15,190 shares during the quarter. Aster Capital Management DIFC Ltd’s holdings in Danaher were worth $238,000 at the end of the most recent quarter.
Several other hedge funds have also recently added to or reduced their stakes in DHR. Gilbert & Cook Inc. boosted its stake in shares of Danaher by 2.5% in the 4th quarter. Gilbert & Cook Inc. now owns 1,749 shares of the conglomerate’s stock valued at $401,000 after purchasing an additional 42 shares in the last quarter. Grimes & Company Inc. grew its holdings in Danaher by 0.6% during the 4th quarter. Grimes & Company Inc. now owns 7,390 shares of the conglomerate’s stock worth $1,696,000 after acquiring an additional 43 shares during the period. Dakota Community Bank & Trust NA boosted its position in shares of Danaher by 16.4% in the 4th quarter. Dakota Community Bank & Trust NA now owns 320 shares of the conglomerate’s stock worth $73,000 after purchasing an additional 45 shares during the last quarter. Howard Capital Management Group LLC grew its stake in shares of Danaher by 4.1% during the third quarter. Howard Capital Management Group LLC now owns 1,229 shares of the conglomerate’s stock worth $342,000 after purchasing an additional 48 shares during the period. Finally, Spinnaker Trust increased its holdings in Danaher by 1.2% in the fourth quarter. Spinnaker Trust now owns 4,304 shares of the conglomerate’s stock valued at $988,000 after purchasing an additional 50 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.
Insiders Place Their Bets
In related news, SVP Brian W. Ellis sold 5,700 shares of the business’s stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the transaction, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at approximately $4,534,149.90. The trade was a 21.98 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 11.10% of the company’s stock.
Wall Street Analysts Forecast Growth
Get Our Latest Stock Analysis on Danaher
Danaher Stock Down 0.6 %
DHR stock opened at $180.71 on Tuesday. The company has a market cap of $129.15 billion, a price-to-earnings ratio of 34.22, a P/E/G ratio of 2.66 and a beta of 0.86. Danaher Co. has a twelve month low of $171.92 and a twelve month high of $281.70. The business has a 50 day moving average price of $208.60 and a two-hundred day moving average price of $233.05. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31.
Danaher (NYSE:DHR – Get Free Report) last released its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, meeting the consensus estimate of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same period in the previous year, the firm earned $2.09 earnings per share. Analysts anticipate that Danaher Co. will post 7.63 EPS for the current fiscal year.
Danaher Increases Dividend
The firm also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be issued a dividend of $0.32 per share. The ex-dividend date of this dividend is Friday, March 28th. This represents a $1.28 dividend on an annualized basis and a yield of 0.71%. This is a boost from Danaher’s previous quarterly dividend of $0.27. Danaher’s dividend payout ratio (DPR) is presently 24.24%.
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Featured Articles
- Five stocks we like better than Danaher
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Options Activity Points to More Volatility for Palantir Stock
- Investing In Preferred Stock vs. Common Stock
- NVIDIA Stock: Oversold, Undervalued — How Low Can It Go?
- Growth Investing: Should You Adopt This Investing Strategy in 2022?
- MicroStrategy Sees Insider Buy-Sell Action in Q1
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.